Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.58 |
| ▸ | DPP4 | P27487 | 2/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6933824 | 1.00 | TAAR1 (0.58) | TAAR1DPP4HTR2AADRA2AADRA2C | |
| SCHEMBL6935886 | 1.00 | TAAR1 (0.58) | TAAR1DPP4HTR2AADRA2AADRA2C | |
| SCHEMBL4678318 | 1.00 | TAAR1 (0.58) | TAAR1DPP4HTR2AADRA2AADRA2C | |
| SCHEMBL4672117 | 1.00 | TAAR1 (0.58) | TAAR1DPP4HTR2AADRA2AADRA2C | |
| SCHEMBL7241817 | 0.94 | TAAR1 (0.52) | TAAR1DPP4HTR2AADRA2AADRA2C | |
| SCHEMBL20525542 | 0.88 | TAAR1 (0.41) | TAAR1DPP4HTR2AHIF1AKDM4E | |
| SCHEMBL2192530 | 0.82 | DPP4 (0.56) | TAAR1DPP4ADRA2AADRA2CLMNA | |
| SCHEMBL4089559 | 0.80 | DPP4 (0.54) | TAAR1DPP4ADRA2AADRA2CLMNA | |
| SCHEMBL22050522 | 0.80 | DPP4 (0.54) | TAAR1DPP4ADRA2AADRA2CLMNA | |
| SCHEMBL7210203 | 0.80 | DPP4 (0.54) | TAAR1DPP4ADRA2AADRA2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190708-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| EP-1314731-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1314732-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190708-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | TAAR1 4384/4885DPP4 32/4885HTR2A 4627/4885 |
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | TAAR1 4384/4885DPP4 32/4885HTR2A 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.